Cited 13 times in
Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.